At Penumbra,innovation,teamwork, andinitiativeare more than values–they are the foundation of a workplace where every individual is encouraged to grow and make a real difference. We believe that the strength of our team lies in our diverse talents and shared passion for improving lives. Ifyou’relooking for a role where your contributions matter, we invite you to join a company that values both personal development and impactful work.

As a leading MedTech company,weprovidecutting-edgesolutions for conditions such as stroke, pulmonary embolism, deep vein thrombosis, and acute limb ischemia.Headquarteredin Alameda, California, Penumbra has over 4,500 employees worldwide and generated revenues of approximately$1.4 billionin 2025.

What is in it for you

Stay Active- Enjoy an annual fitness subsidy to support your healthy lifestyle.

Support & Well-Being- Benefit from our comprehensive Employee Assistance Program, providing guidance and support in times of need.

Family First- Receive two weeks of paid Family Care Leave to support a sick family member or in the case of bereavement.

Vacation Time- In addition to your regular vacation days, enjoy paid time off on December 24th and 31st.

A Team That Inspires-Work alongside a diverse, open-minded, and supportive team that encourages personal and professional growth.

Drive in Style- Take advantage of a company car for private use, making your daily commute easier and more comfortable.

Accident Insurance- Stay protected with comprehensive accident insurance during all business trips.

Main Responsibilities

As a Territory Manager Neurovascular, you will drive commercial success in your region by expanding existing accounts and acquiring new business across neurovascular specialties. You own your territory end-to-end and act as a trusted partner to healthcare professionals, supporting them in delivering the best possible patient outcomes.

This is a field-based role requiring strong clinical engagement, commercial acumen, and the ability to operate independently in a dynamic environment.

Your Tasks include:

Drive territory growth through new business acquisition and expansion of existing accounts in neurovascular specialties

Own full territory management including account strategy, segmentation, forecasting, and revenue responsibility

Build and maintain strong clinical relationships, including KOL engagement and regular customer interaction

Develop a deep understanding of customer needs and clinical practices through regular time in the lab, planned customer visits, and ongoing market observation

Support product adoption through training, product demonstrations, and clinical education

Position products effectively within pricing and reimbursement frameworks to optimize commercial outcomes

Monitor market trends and competitors, translating insights into actionable commercial strategies

Collaborate cross-functionally with Marketing, Customer Service, and internal stakeholders to execute go-to-market plans

What we are looking for

Bachelor’s degree in Business, Life Sciences, or a related field

3+ years of sales experience in medical devices or healthcare, with the ability to quickly ramp up and drive territory growth

Experience in neurovascular, neurosurgery, interventional radiology, or related specialties preferred; broader vascular, endovascular, or cardiology experience will also be considered

Proven track record of achieving sales targets and growing existing and new accounts

Strong understanding of anatomy, clinical applications, and procedural environments

Fluent in English, both spoken and written

Excellent communication, influencing, and negotiation skills

Entrepreneurial, proactive, and self-driven mindset

Ability to work independently, prioritize effectively, and successfully manage a field-based territory

Strong relationship-building skills with healthcare professionals and internal stakeholders

Collaborative, adaptable, and team-oriented approach with a high level of energy and initiative

Valid driver’s license

As we require fluent English skills and the recruiting process will involve English-speaking colleagues, we look forward to receiving your CV in English.

Skills and a Cultural Match

At Penumbra, we value your skills and qualifications above all else. We welcome candidates of any gender, ethnicity, religion, sexual orientation, or age. If you're skilled and a good match for our culture of collaboration, we want you on our team. To learn more about Penumbra's commitment to being an equal opportunity employer, please take a look at our AAP-Policy-Statement.

About the company

Penumbra develops and sells medical devices for neurovascular and peripheral vascular conditions. Its products assist doctors in treating stroke and other vascular diseases by delivering—through systems like the Penumbra System and Indigo System—catheters, coils, and evacuation devices that are placed inside blood vessels. The company differentiates itself with a broad, integrated portfolio and a global sales network across Europe and the Americas, emphasizing engineering and clinical performance. Its goal is to improve patient outcomes and sustain growth by investing in ongoing research and development to expand its capabilities.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Alameda, California

Founded

2004

Get referred to Penumbra Inc

See people who can refer or advise you

Simplify's Take

What believers are saying

Q2 2026 revenue reached $390.0 million, up 14.9%, with 67.9% gross margin.
September 9, 2026 Link launch expands Lightning Bolt workflows for resistant clot.
Magnendo's $18 million round, led by Penumbra, extends its stroke robotics ecosystem.

What critics are saying

June 3, 2026 RED 68 recall flags manufacturing defects and franchise reliability.
Incuvate sued Penumbra on August 19, 2026 over THUNDERBOLT patents; injunction risk.
Boston Scientific's acquisition still requires approvals; any 2026 slip derails employee retention and valuation.

What makes Penumbra Inc unique

Penumbra's CAVT platform pairs computer control with thrombectomy; THUNDERBOLT cleared FDA in 2026.
Broad neurovascular and peripheral portfolios sell into over 100 countries.
Deep physician evidence engine adds leaders like Donald Frei and published stroke studies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Paid Vacation
Paid Sick Leave
Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

Business Insider

Oct 2nd, 2026

RBC Capital keeps their Hold rating on Penumbra (PEN).

RBC Capital keeps their Hold rating on Penumbra (PEN). Oct. 2, 2026, 09:47 PM In a report released on October 1, Kendall Au from RBC Capital maintained a Hold rating on Penumbra, with a price target of $374.00. The company's shares closed yesterday at $318.00. According to TipRanks, Au is an analyst with an average return of -3.6% and a 22.22% success rate. Au covers the Healthcare sector, focusing on stocks such as Becton Dickinson, GE Healthcare Technologies Inc, and Boston Scientific. Penumbra has an analyst consensus of Hold, with a price target consensus of $358.40. Based on Penumbra's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $390.05 million and a net profit of $34.81 million. In comparison, last year the company earned a revenue of $339.46 million and had a net profit of $45.27 million Read More on PEN:

Penumbra, Inc.

Sep 9th, 2026

Penumbra launches Link, expanding vascular thrombectomy options for physicians.

Penumbra launches Link, expanding vascular thrombectomy options for physicians. September 9, 2026 Penumbra recently launched the Link(TM) clot capture device designed to support the removal of arterial thrombus when used in conjunction with Lightning Bolt(R) technology. Link is designed to lock and hold clot, connecting to the power of computer assisted vacuum thrombectomy (CAVT(R) to secure and maximize clot extraction. "Link expands the toolkit available to physicians by providing an additional mechanical clot engagement option that can help address resistant thrombus while maintaining aspiration with CAVT," said James F. Benenati, MD, FSIR, chief medical officer at Penumbra. "By offering clinicians greater flexibility in challenging cases, it has the potential to improve procedural efficiency and support more effective patient care." Deployed into thrombus, Link engages and mobilizes organized clot while aspiration facilitates clot ingestion into the aspiration catheter. Designed to complement existing Lightning Bolt workflows, Link can be incorporated when additional mechanical clot engagement is desired, without requiring a fundamentally different procedural approach. Early physician experience has highlighted Link's ability to work synergistically with Lightning Bolt technology. "Link appeared to provide a secure hold on the embolus, allowing Bolt to more effectively aspirate the residual thrombus," said Thomas Heafner, MD, after using Link with Bolt 7. "Combining Link with Lightning Bolt resulted in rapid and effective clot clearance." "Link represents an important advancement in our CAVT portfolio, providing an additional option for engaging and removing challenging blood clots," said Shruthi Narayan, president of Penumbra. "Link was designed to bring a new dimension to thrombectomy by combining secure clot engagement with the power of modulated aspiration, offering clinicians an additional therapeutic option for some of the most challenging cases. This launch reflects our continued commitment to developing technologies that advance vascular care and improve patient outcomes." Designed to Secure Clot and Maximize Extraction LINK is designed to lock and hold clot while leveraging the power of CAVT to support clot removal. Its unique architecture is engineered to minimize vessel wall engagement and support atraumatic clot extraction. Important Safety Information Additional information about Penumbra's products can be located on Penumbra's website at https://www.penumbrainc.com/products/peripheral-thrombectomy-cavt/. The clinical results presented herein are for informational purposes only and may not be predictive for all patients. Individual results may vary depending on patient-specific attributes and other factors. Caution: Federal (USA) law restrictions these devices to sale by or on the order of a physician. Prior to use, please refer to the Instructions for Use (IFU) for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. For the complete Penumbra IFU Risk Summary Statements, visit: peninc.info/risk. Please contact your local Penumbra representative for more information.

GlobeNewswire

Aug 25th, 2026

Incuvate files patent infringement lawsuit against Penumbra.

Incuvate files patent infringement lawsuit against Penumbra. Complaint alleges Penumbra's THUNDERBOLT(TM) system infringes five Incuvate patents covering blood-clot detection technology. August 25, 2026 15:28 ET | Source: Incuvate LLC IRVINE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) - Incuvate, LLC today announced that it has filed a patent-infringement lawsuit against Penumbra, Inc. in the U.S. District Court for the Northern District of California. The lawsuit, filed August 19, 2026, alleges that Penumbra's recently launched THUNDERBOLT(TM) Neurovascular Thrombectomy System and related components infringe five Incuvate patents directed to real-time aspiration monitoring technology used in catheter-based thrombectomy procedures. Incuvate's patents cover technology that uses pressure sensors, microprocessors, and pre-set pressure thresholds or differentials to provide real-time visual and audible feedback during aspiration procedures. Incuvate alleges that this technology helps distinguish between clot engagement and blood flow and provides clinicians with valuable information during thrombectomy procedures. The complaint identifies Penumbra's THUNDERBOLT system, Penumbra ENGINE vacuum source, THUNDERBOLT tubing and module, and associated RED Reperfusion Catheters as accused products. Incuvate alleges that these products use patented technology to detect flow conditions, including the presence of clot, and provide users with feedback regarding flow status. Through this lawsuit, Incuvate seeks to hold Penumbra accountable for what Incuvate alleges is Penumbra's unauthorized and willful infringement of the technologies embodied in the asserted patents. Incuvate is seeking damages, injunctive relief, and other remedies described in the complaint. A copy of the complaint is available through PACER Monitor in Incuvate, LLC v. Penumbra, Inc., Case No. 4:26-cv-08658. About Incuvate Incuvate works with medical device entrepreneurs to develop early-stage concepts into innovative products and leads them to market via new companies it finances, builds, and manages. Learn more at incuvatellc.com Media Contact Lance Capel Director of Strategy & External Relations [email protected]

Penumbra, Inc.

Aug 10th, 2026

Dr. Donald Frei joins Penumbra as Associate Chief Medical Officer of Neuro.

Dr. Donald Frei joins Penumbra as Associate Chief Medical Officer of Neuro. August 10, 2026 Penumbra announced today that Donald Frei, MD, FSNIS, FACR, will serve as Associate Chief Medical Officer of Neuro. A nationally recognized neurointerventional surgeon, Dr. Frei brings clinical and research expertise in stroke and neurovascular care to Penumbra's clinical leadership team. Reporting to James Benenati, MD, FSIR, Chief Medical Officer of Penumbra, Dr. Frei will help guide Penumbra's neurovascular clinical strategy, support evidence development, and collaborate with physicians worldwide to advance patient care. "Dr. Frei has dedicated his career to advancing neurovascular care, from pioneering faster stroke recanalization protocols to helping establish the clinical evidence behind therapies that improve patient outcomes," said Dr. Benenati. "His deep clinical expertise, commitment to innovation, and passion for patient care will be invaluable as we continue to expand the impact of our neurovascular technologies around the world." Throughout his career, Dr. Frei has authored more than 200 peer-reviewed publications and contributed to the advancement of neurovascular therapies through extensive clinical research and evidence generation. Recently, Dr. Frei was the co-principal investigator of the THUNDER Study, which demonstrated that Penumbra's CAVT(TM)(Computer Assisted Vacuum Thrombectomy) platform with THUNDERBOLT technology is safe and effective, paving the way for FDA clearance and CE Mark. Dr. Frei was also instrumental in launching the Get Ahead of Stroke(R) campaign to improve stroke triage and expand access to life-saving neuroendovascular care. "With the recent launch of CAVT with THUNDERBOLT, the neurovascular space is prime for transformation," said Dr. Frei. "I look forward to this opportunity to help advance innovation, generate evidence, deepen trust and closer collaboration with our medical and professional societies, and improve access to care so more patients are able to benefit from the latest technology." Dr. Frei is a leading board-certified neurointerventional surgeon and is a past president of the Society of NeuroInterventional Surgery. He earned his medical degree from the University of Cincinnati College of Medicine and completed his residency training in diagnostic radiology at Tulane University Medical Center. He subsequently completed fellowship training in neuroradiology and endovascular surgical neuroradiology at Washington University's Mallinckrodt Institute of Radiology. He has been recognized as a Fellow of the Society of NeuroInterventional Surgery (FSNIS) and a Fellow of the American College of Radiology (FACR).

Yahoo Finance

Jul 30th, 2026

Penumbra reports $390M Q2 revenue, up 14.9% ahead of Boston Scientific acquisition

Penumbra reported second quarter 2026 revenue of $390.0 million, up 14.9% year-over-year. The thrombectomy company's global thrombectomy revenue reached $259.0 million, increasing 12.5%, whilst embolization and access revenue grew 20.0% to $131.1 million. Gross profit margin improved to 67.9%, up 1.9 percentage points from the prior year. Operating income was $41.0 million, with net income of $34.8 million. Total operating expenses stood at $223.9 million, including $6.9 million in acquisition-related costs. Due to Boston Scientific's pending acquisition of Penumbra, the company will not provide full-year 2026 guidance or host a conference call to discuss results. Penumbra operates in over 100 countries, focusing on thrombectomy technologies for conditions including ischaemic stroke and pulmonary embolism.

Penumbra Inc

Neurovascular Territory Manager - Central & South UK

About the job